12th May 2026 01:06
4basebio PLC - Cambridge, England-based life sciences company - Launches high-capacity single stranded-DNA for therapeutics. The company says the platform, ssDNA, will "accelerate the development of safer, more precise genetic therapies by targeting gene editing, advanced cell engineering and innovative nucleic acid-based medicines." 4basebio will showcase its proprietary advancements at the American Society for Gene & Cell Therapy Annual Meeting in Boston on May 14, 2026.
Chief Executive Officer Amy Walker says: "We are empowering our partners to design therapies without the conditional constraints of length or sequence complexity...enhancing the reliability and safety profile required for life-changing therapeutics."
Current stock price: 450.00 pence
12-month change: down 60%
By John Robaina, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
4basebio Plc